Clinical Study

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate The Efficacy And Safety Of Sa237 As Monotherapy In Patients With Neuromyelitis Optica (Nmo) And Neuromyelitis Optica Spectrum Disorder (Nmosd).

Posted Date: Sep 15, 2016

  • Investigator: Aram Zabeti
  • Specialties: Multiple Sclerosis, Neurology
  • Type of Study: Drug

Neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD) are disorders of the immune system which cause damage to nerve coverings. The purpose of this research study is to find out if SA237 is safe and effective in patients with NMO or NMOSD. SA237 is an experimental drug which is not approved for the treatment of NMO/NMOSD. At this time, there are no approved treatments available for the prevention or relapse of NMO/NMOSD. We hope to learn from this study whether SA237 is better at preventing relapses than a placebo (an injection containing no drug). SA237 is an antibody in a liquid form that is injected under your skin. This antibody attaches to a chemical in the body that can cause inflammation and many doctors believe this contributes to NMO. SA237 may help prevent these relapses but it is not certain at this time. You are free to choose as to whether you wish to consent to one or more of these additional tests. Should you choose not to, this will in no way affect your participation in the rest of the study.


You Are Being Asked To Take Part In This Research Study Because You Are 18 To 74 Years Of Age And You Have Been Diagnosed With Nmo Or Nmosd.


Neuromyelitis Optica Spectrum Disorder , Multiple Sclerosis, Nmo, Neuromyelitis Optica, Nmosd

For More Information:

Katie Krier